Ashish Udeshi, MD
Pain Medicine · Melbourne, FLNPI 1891968079
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $11,434 of the $16,773 with a category attached, or 68.2%. 45 manufacturers reported payments, led by Boston Scientific at 24.4% of the total. 2025 is the largest year on record at $6,399, 6.4 times the $1,002 reported in 2019.
Across 426 payments — averaging $39.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$4K
- Medtronic$3K
- Vertos Medical, Inc.$1K
- Spinal Simplicity, LLC$1K
- Si-bone, Inc.$993
- Relievant Medsystems, Inc.$834
- plus $5K from 39 others
Across 72 payments — averaging $1196.05 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$52K
- Medtronic$23K
- Vertiflex, Inc.$12K
What the payments were for
- Consulting fees$1,0636%
- Travel & lodging$4,10224%
- Food & beverage$11,43468%
- Education$1751%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Intracept$3,707
- HA MINUTEMAN G3-R$1,129
- INTELLIS ADAPTIVESTIM$914
- mild Device Kit$689
- LIBERTY SI$525
- IFUSE IMPLANT SYSTEM$433
- SYNCHROMEDII$421
- NURTEC ODT$233
- MULTIGEN 2$156
- TRELEGY ELLIPTA$107
- ETERNA$107
How this compares
$16,773 in reported general payments places this provider in the 85th percentile of 596 pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 164 | $73,537 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 988 | $31,411 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 1,103 | $25,434 |
| LyricaPregabalin | 13 | $12,132 |
| OxycontinOxycodone Hcl | 22 | $10,678 |
| Morphine Sulfate ErMorphine Sulfate | 329 | $8,857 |
| Pregabalin | 372 | $8,720 |
| Oxycodone Hcl | 398 | $7,864 |
| Fentanyl | 48 | $4,773 |
| Tramadol Hcl | 400 | $3,335 |
| Buprenorphine | 22 | $3,333 |
| Tramadol Hcl ErTramadol Hcl | 29 | $2,438 |
| Morphine Sulfate | 73 | $1,504 |
| Naloxone Hcl | 19 | $1,196 |
| Gabapentin | 74 | $1,135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $709 | $73,537164 claims |
| PfizerLyrica | $38 | $12,13213 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate | $36 | $4,83795 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 596 pain medicine providers in Florida.
Other pain medicine in Melbourne
- Rohan SarnaMelbourne$29K
- Nicholas GiordanoMelbourne$24K
- Lee NeubertMelbourne$19K
- Jeffrey GudinMiami$356K
- Joseph PergolizziNaples$333K
- Ramon Cuevas-TrisanRiviera Beach$220K
- Navdeep JassalLakeland$163K
- Mark-Friedrich HurdleJacksonville$140K
- Rodolfo GariTampa$120K
- Stephen PylesOcala$115K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.